Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis

Table 3

Meta-analysis of BIM deletion polymorphism associated with PFS.

Subgroup	No. of studies	BIM deletion/total	(%)	Pooled HR	95% CI
Overall	20	475/3003	63.1	1.35	1.10-1.64	0.003
Country
South Korea	3	63/467	0	0.84	0.61-1.17	0.310
China	12	312/1972	58.9	1.32	1.05-1.66	0.019
Others	5	100/564	72.8	1.80	1.09-2.99	0.022
HR estimates
Reported	14	365/2275	69.3	1.39	1.07-1.81	0.013
Estimated	6	110/728	44.6	1.28	0.95-1.71	0.100
Survival analysis
Univariate	13	333/2104	44.8	1.10	0.91-1.33	0.331
Multivariate	7	142/899	54.8	1.89	1.37-2.62	<0.001

PFS: progression-free survival; HR: hazard ratio. All HRs were pooled by a random effects model.